Welcome to our dedicated page for Agenus news (Ticker: AGEN), a resource for investors and traders seeking the latest updates and insights on Agenus stock.
Agenus Inc (AGEN) is a clinical-stage biotechnology company pioneering novel immunotherapies to combat cancer and infectious diseases. This page provides centralized access to official press releases, financial updates, and scientific developments from Agenus, offering stakeholders a reliable resource for tracking the company’s progress.
Investors and researchers will find timely updates on clinical trial milestones, regulatory filings, and strategic partnerships, alongside analyses of AGEN’s proprietary platforms like Retrocyte Display™ antibody technology. The curated news collection enables efficient monitoring of the company’s immuno-oncology pipeline and manufacturing advancements through its integrated cGMP facilities.
Key categories include earnings reports, therapy development updates, licensing agreements, and peer-reviewed research highlights. Bookmark this page to stay informed about AGEN’s innovations in checkpoint modulators, cell therapies, and vaccine adjuvants without navigating multiple sources.
Agenus (NASDAQ: AGEN) has reported its Q4 and full-year 2024 financial results, highlighting significant operational improvements and cost reductions. The company achieved a Q4 2024 operational cash burn of $28.7 million and aims to reduce annual burn to approximately $50 million by mid-2025.
The company's botensilimab/balstilimab (BOT/BAL) program demonstrated promising clinical outcomes in resistant tumor types, particularly in colorectal cancer treatment. Data presented at ASCO-GI 2025 showed meaningful, durable responses across neoadjuvant and later lines of CRC treatment.
Financial highlights include:
- Year-end 2024 cash balance of $40.4 million (down from $76.1 million in 2023)
- 2024 revenue of $103.5 million
- Net loss of $232.3 million ($10.59 per share)
- Q4 revenue of $26.8 million with net loss of $46.8 million ($2.04 per share)
Agenus Inc. (NASDAQ: AGEN) has presented significant immuno-oncology data across multiple medical conferences and publications in 2024-2025, highlighting advances in cancer immunotherapy. The company's key antibody candidates, botensilimab (BOT) and balstilimab (BAL), have been evaluated in approximately 1,100 patients across 60+ centers worldwide.
The BOT/BAL combination has shown clinical responses across nine tumor types, including traditionally 'cold' tumors. Notable results include:
- High major pathological response rates in colorectal cancer (CRC) through the NEST and UNICORN trials
- 19% response rate in microsatellite stable (MSS) metastatic CRC patients with no liver metastases
- 71% objective response rate in combination with FOLFOX chemotherapy and bevacizumab in MSS metastatic CRC
- 19.2% overall response rate in sarcoma patients with 69% 12-month survival rate
Agenus (Nasdaq: AGEN), an immuno-oncology company, has announced its participation in the B. Riley Securities Precision Oncology & Radiopharma Investor Conference in New York. The company's Chief Commercial Officer, Robin Taylor, Ph.D., will join a panel discussion focused on 'What It Takes to Move the Needle in Improving Responses in Colorectal Cancer.' The event is scheduled for February 28th, 2025, from 1:00-2:00 p.m. ET. This in-person conference requires interested attendees to contact B. Riley for participation details.
Agenus Inc. (Nasdaq: AGEN), a leader in developing novel immunological agents to treat various cancers, has announced it will release its fourth quarter and full year 2024 financial results before market opening on Tuesday, March 11th.
Following the release, Agenus executives will host a conference call and webcast at 8:30 a.m. ET to discuss the results and provide a corporate update. Interested parties can register to access the dial-in numbers with Conference ID: 73242.
A live webcast and replay of the conference call will be available on the company's investor relations website and through the provided event link.
Agenus (NASDAQ: AGEN) presented new data at the AACR IO Annual Meeting regarding their Phase 2 study combining botensilimab (BOT) and balstilimab (BAL) with MiNK Therapeutics' agenT-797 in refractory gastric cancer patients.
The key findings demonstrate that adding agenT-797 (an allogeneic invariant natural killer T cell therapy) to BOT/BAL treatment resulted in:
- Robust immune activation with elevated interferon-gamma levels
- Increased tumor-infiltrating lymphocytes
- Enhanced peripheral memory T-cell activation
- Potential for improved outcomes when administered before standard chemotherapy
The research suggests this combination therapy could effectively transform immunologically 'cold' tumors into 'hot' immune inflamed tumors, potentially offering new treatment options for late-line gastric cancer patients, including those who are PD-1 refractory.
Agenus (NASDAQ: AGEN) announced two upcoming presentations featuring BOT/BAL at the AACR IO Annual Meeting in Los Angeles (February 23-26). The first presentation will showcase interim data from a Phase 2 study combining botensilimab and balstilimab (BOT/BAL) with MiNK Therapeutics' iNKT cell therapy (AgenT-797) in refractory gastric cancer patients.
The second presentation will be a Trial-in-Progress poster highlighting data from an ongoing Phase 1/2 study of BOT/BAL in first-line MSS colorectal cancer. The presentations are scheduled for February 24th and 25th, covering biomarker analysis and treatment optimization strategies.
Agenus (NASDAQ: AGEN) has announced two upcoming presentations featuring BOT/BAL at the AACR IO Annual Meeting in Los Angeles from February 23-26. The first presentation will showcase interim data from a Phase 2 study combining botensilimab and balstilimab (BOT/BAL) with MiNK Therapeutics' iNKT cell therapy, AgenT-797, in patients with refractory gastric cancer.
The second presentation, a Trial-in-Progress poster, will focus on data from an ongoing Phase 1/2 study of BOT/BAL in first-line MSS colorectal cancer. The presentations are scheduled for Monday, February 24th, with the poster session running from 1:45-4:45 p.m. PST and the biomarker analysis presentation from 1:39-1:45 p.m. PST.
Agenus (NASDAQ: AGEN) published results in the Journal of Clinical Oncology from its study of botensilimab (BOT) combined with balstilimab (BAL) in patients with relapsed/refractory metastatic sarcomas. The Phase 1 trial demonstrated significant efficacy across multiple sarcoma subtypes, including traditionally resistant forms.
Key results include an overall response rate of 19.2% in the study population (n=52), with 27.8% response rate in angiosarcoma patients (n=18). The disease control rate reached 65.4%, with 4.4 months median progression-free survival. The treatment showed a remarkable median duration of response of 21.7 months and 69% overall survival rate at 12 months.
The combination therapy demonstrated a manageable safety profile, with diarrhea/colitis (grade 3, 6.3%) as the most common treatment-related adverse event, effectively managed with steroids and TNF-alpha inhibitors. No Grade 4 or 5 adverse events were reported.
Agenus (NASDAQ: AGEN) presented new data on botensilimab (BOT) and balstilimab (BAL) combination therapy at ASCO GI, demonstrating significant potential in colorectal cancer (CRC) treatment. The data comes from multiple studies involving over 1,100 patients across 60+ centers worldwide.
Key findings include results from two neoadjuvant studies (UNICORN and NEST) with 80+ patients, showing promising pathological complete response rates: 93% in dMMR/MSI-H tumors and 29% in pMMR/MSS tumors. In first-line treatment, the combination with FOLFOX-Bevacizumab achieved 71% overall response rate in 14 patients.
A global Phase 2 study with 234 patients demonstrated 19% overall response rate and 55% disease control rate in refractory MSS mCRC, with 70% of responses ongoing at data cut-off. The therapy showed particular promise in treating microsatellite stable (MSS) CRC tumors, which represent 85-95% of CRC cases and typically don't respond to immunotherapy.
Agenus (NASDAQ: AGEN) announced five presentations featuring botensilimab (BOT) plus balstilimab (BAL) at the upcoming ASCO GI Symposium (January 23-25, 2025). The presentations will showcase BOT/BAL's activity across three distinct colorectal cancer settings: late-line metastatic, first-line, and neoadjuvant treatment.
The studies demonstrate BOT/BAL's consistent activity in microsatellite stable (MSS) colorectal cancer, which represents over 80% of CRC cases with treatment options, as well as microsatellite instability-high (MSI-H) CRC. An additional presentation will feature BOT/BAL and invariant natural killer T cells (iNKTs) in refractory gastric cancer patients.
FAQ
What is the current stock price of Agenus (AGEN)?
What is the market cap of Agenus (AGEN)?
